STOCK TITAN

Horizon Technology Finance Corp - HRZN STOCK NEWS

Welcome to our dedicated news page for Horizon Technology Finance (Ticker: HRZN), a resource for investors and traders seeking the latest updates and insights on Horizon Technology Finance.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Horizon Technology Finance's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Horizon Technology Finance's position in the market.

Rhea-AI Summary
BioVaxys Technology Corp. completes the acquisition of IMV Inc.'s assets, expanding its portfolio in oncology, infectious disease, allergy desensitization, and autoimmune diseases. The acquisition includes clinical-stage programs like Maveropepimut-S, with plans for organic growth through licensing and partnership opportunities. The Company aims to leverage the DPX™ and HapTenix© platforms for targeted immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
acquisition
-
Rhea-AI Summary
BioVaxys Technology Corp. completes the acquisition of IMV Inc.'s assets, expanding its portfolio in oncology, infectious disease, allergy desensitization, and autoimmune diseases. The acquisition includes clinical-stage programs like Maveropepimut-S, with plans for organic growth through licensing and partnership opportunities. The Company aims to leverage the DPX™ and HapTenix© platforms for targeted immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
acquisition
-
Rhea-AI Summary
Horizon Technology Finance Corporation (HRZN) plans to release financial results for Q4 2023 on February 27, 2024. The conference call to discuss the results will be held on February 28, 2024, featuring key executives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
earnings
Rhea-AI Summary
BioVaxys Technology Corp. acquires IMV's extensive technology portfolio through an Asset Purchase Agreement, including the DPX™ immune educating platform. The transaction involves upfront cash payment, milestone payments, royalties, and shares of BioVaxys common stock. BioVaxys gains access to DPX™ antigen delivery platform for cancer immunotherapies, specifically maveropepimut-S. The acquisition includes patents, patent applications, international filings, trademarks, and intellectual property. BioVaxys aims to expand its pipeline in oncology, infectious diseases, and immunological fields, positioning itself as a key player in cancer immunotherapy and other verticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.17%
Tags
acquisition
-
Rhea-AI Summary
BioVaxys Technology Corp. acquires IMV's extensive technology portfolio through an Asset Purchase Agreement, including the DPX™ immune educating platform. The transaction involves upfront cash payment, milestone payments, royalties, and shares of BioVaxys common stock. BioVaxys gains access to DPX™ antigen delivery platform for cancer immunotherapies, specifically maveropepimut-S. The acquisition includes patents, patent applications, international filings, trademarks, and intellectual property. BioVaxys aims to expand its pipeline in oncology, infectious diseases, and immunological fields, positioning itself as a key player in cancer immunotherapy and other verticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
acquisition
-
Rhea-AI Summary
Horizon Technology Finance Corporation (NASDAQ: HRZN) originated $63.4 million of new loans in Q4, ending 2023 with a committed backlog of $218 million. The portfolio update for the fourth quarter ended December 31, 2023, includes significant originations, liquidity events, partial paydowns, principal payments received, commitments, pipeline and term sheets, and details about the warrant and equity portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
earnings
Rhea-AI Summary
Parse Biosciences (HRZN) secures $50 million in financing to expand single cell sequencing solutions and serve academic, biotech, and pharma customers. The funding, led by Soleus Capital, will drive the company's product portfolio and commercial reach, bringing total funding to over $100 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary
Horizon Technology Finance Corporation (NASDAQ: HRZN) has declared monthly cash distributions of $0.11 per share for January, February, and March 2024, as well as a special distribution of $0.05 per share for December 2023. Since its IPO in 2010, Horizon has paid a total of $237 million in distributions to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
none
-
Rhea-AI Summary
Horizon Technology Finance Corporation (NASDAQ: HRZN) announced its financial results for Q3 2023. Net investment income per share was $0.53, NAV per share was $10.41. The debt portfolio yield was 17.1%. The portfolio grew by 15% YoY to $729 million. The Horizon Platform ended the quarter with a committed backlog of $222 million, including $202 million in HRZN commitments. Regular monthly distributions totaling $0.33 per share through March 2024 and a $0.05 special distribution payable in December 2023 were declared.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
earnings
Rhea-AI Summary
Horizon Technology Finance Corporation plans to release financial results for Q3 2023 on October 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Horizon Technology Finance Corp

OTC:HRZN

HRZN Rankings

HRZN Stock Data

433.63M
1.31%
5.22%
1.38%
Securities and Commodity Exchanges
Finance and Insurance
Link
United States
Farmington

About HRZN

horizon is a venture lending platform that thoughtfully and creatively provides structured debt products to life science and technology companies. horizon's experienced team of investment and operations professionals have been providing debt capital to some of the most exciting companies for decades. since 2004, horizon has directly originated and invested more than $1.2 billion in venture loans to more than 200 growing companies. with horizon's industry knowledge and proven reliability as a capital source, combined with its long-standing relationships in the venture capital community, the horizon team shares the optimism of its portfolio companies and their commitment to overcome any obstacles to success. horizon is opportunistic and forward-looking. taking the long view does more than bridge the financial gap. it allows horizon's portfolio companies to get from where they are to where they want to be. headquartered in farmington, connecticut, horizon technology finance corporation (n